scholarly journals Cost Effectiveness of Exemestane versus Tamoxifen in Post-Menopausal Women with Early Breast Cancer in Germany

Breast Care ◽  
2009 ◽  
Vol 4 (6) ◽  
pp. 389-396 ◽  
Author(s):  
Sebastian Braun ◽  
Thomas Mittendorf ◽  
Thomas Menschik ◽  
Wolfgang Greiner ◽  
Johann-Matthias von der Schulenburg
Keyword(s):  
Breast Cancer ◽  
Cost Effectiveness ◽  
Early Breast Cancer ◽  
Menopausal Women ◽  
Post Menopausal

scholarly journals The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer

1998 ◽  
Vol 79 (2) ◽  
pp. 311-315 ◽  
Author(s):  
M Dowsett ◽  
J S Tobias ◽  
A Howell ◽  
G M Blackman ◽  
H Welch ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Menopausal Women ◽  
Post Menopausal

scholarly journals Cost-effectiveness Analysis of Ribociclib plus Letrozole versus Palbociclib plus Letrozole in the United Kingdom

10.36469/9725 ◽  
2019 ◽  
Vol 6 (2) ◽  
pp. 20-31 ◽  
Author(s):  
Gaurav Suri ◽  
David Chandiwana ◽  
Adam Lee ◽  
Rohit Mistry
Keyword(s):  
Breast Cancer ◽  
Cost Effectiveness ◽  
Advanced Breast Cancer ◽  
Cost Savings ◽  
Cost Effective ◽  
Advanced Breast ◽  
Lifetime Horizon ◽  
Menopausal Women ◽  
Post Menopausal ◽  
The Cost

Objective: To evaluate the cost-effectiveness of ribociclib plus letrozole versus palbociclib plus letrozole in post-menopausal women with hormone receptor positive (HR+) and human epidermal growth receptor 2 negative (HER2-) advanced breast cancer from a UK payer perspective. Methods: A cohort-based partitioned survival model was developed to evaluate the cost-effectiveness of ribociclib plus letrozole versus palbociclib plus letrozole in post-menopausal women with HR+/HER2- advanced breast cancer over a lifetime horizon. The analysis was carried out from a National Health Services and Personal Social Services perspective, and results are presented in incremental costs per quality adjusted life years. Clinical data from three randomized controlled trials (MONALEESA-2, PALOMA-1 and PALOMA-2 studies) were used, and supplemented with available real world evidence. Costs categories comprised of drug acquisition, medical management, and treatment of adverse events. Healthcare resource utilization data were identified from literature and unit costs sourced from secondary sources. Utility values were derived from MONALEESA-2 study and were supported with values identified from literature. Both deterministic and probabilistic analyses were carried out to assess uncertainty. Results: In the base case, treatment with ribociclib plus letrozole increased mean progression free survival (PFS) by 4.1 months and overall survival by 5.0 months compared to palbociclib plus letrozole. Further, treatment with ribociclib plus letrozole resulted in cost-savings of £8464 and incremental QALYs of 0.261, demonstrating that treatment with ribociclib plus letrozole is dominant to treatment with palbociclib plus letrozole. The probabilistic analysis also yielded mean cost-savings of £7914 and mean QALY gain of 0.273. At willingness-to-pay threshold of £30 000 per QALY, treatment with ribociclib plus letrozole had a 92% probability of being cost-effective compared to palbociclib and letrozole. Conclusions: The results of the analysis demonstrate that ribociclib plus letrozole treatment is both cost-saving and a cost-effective option amongst the available cyclin dependent kinase 4/6 inhibitors for the treatment of post-menopausal women with advanced breast cancer. The biggest driver of the cost savings were the lower acquisition costs of ribociclib.

scholarly journals Cost-Effectiveness of Lapatinib plus Letrozole in Post-Menopausal Women with Hormone Receptor- and HER2-Positive Metastatic Breast Cancer

Breast Care ◽  
2013 ◽  
Vol 8 (6) ◽  
pp. 429-437 ◽  
Author(s):  
Thomas E. Delea ◽  
Carol Hawkes ◽  
Mayur M. Amonkar ◽  
Konstantinos Lykopoulos ◽  
Stephen R. D. Johnston
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Cost Effectiveness ◽  
Hormone Receptor ◽  
Metastatic Breast ◽  
Her2 Positive ◽  
Menopausal Women ◽  
Post Menopausal

Upper limb function: Comparison of postmenopause women with and without a history of early breast cancer.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e20578-e20578
Author(s):  
Nasim Foroughi ◽  
Mi-Joung Lee ◽  
Sharon Kilbreath
Keyword(s):  
Breast Cancer ◽  
Cancer Treatment ◽  
Early Breast Cancer ◽  
Upper Limb ◽  
Breast Cancer Treatment ◽  
Community Dwelling ◽  
Control Group ◽  
Menopausal Women ◽  
History Of ◽  
Post Menopausal

e20578 Background: Long term upper limb impairments following early breast cancer treatment are commonly reported in women years following surgery. However, the extent to which the symptoms are related to menopause and ageing, rather than cancer, has not been explored. This study aimed to compare upper limb strength, shoulder forward flexion range of motion (FF RoM), and presence of impairments in post menopausal women with and without a history of breast cancer. Methods: Community–dwelling age and body mass index (BMI)-matched post menopausal women with (n=40) and without a history of early breast cancer treatment (n=40) participated. Women with other types of cancer, metastatic cancer, and significant neurological or musculoskeletal history unrelated to breast cancer were excluded. Peak shoulder muscle strength was assessed using pneumatic resistance machines and FF RoM with a digital inclinometer. Participants completed the Disability of arm, shoulder and hand (DASH) questionnaire. Between groups comparison were made using analysis of co-variance with age and BMI as confounding variables. Results: Upper limb strength (206.22±45.0 vs. 225.36±86.9 Nm/kg, p=0.091) and FF RoM (166.75±7.9◦ vs. 170.14±6.9◦, p=0.259) were not significantly different between the study and the control group. There were no significant differences between the groups on any of the DASH sub scores (pain: 9.18±8.1 vs. 8.62±8.2, P=0.770). Conclusions: Upper limb impairments are often presumed to be a consequence of surgical procedures in women with breast cancer. However, some of the symptoms women perceive years following surgery may be related to the changes due to aging or menopause rather than cancer treatment.

Sign in / Sign up

Export Citation Format

Share Document